CompletedPhase 3NCT05051761

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Principal Investigator
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Intervention
Jaktinib(drug)
Enrollment
425 enrolled
Eligibility
18-65 years · All sexes
Timeline
20212023

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05051761 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials